Relationship between the Therapeutic Dose of Arsenic Trioxide and Relapse in Acute Promyelocytic Leukemia

Huai Yu Wang; Hui Yun Zhang; Yuan Liu; Xin Xin Zhang; Sha Gong; Li Mei Chen; Meng Chang Wang; Jie Ying Xi; Xin Liu

doi:10.7534/j.issn.1009-2137.2018.03.012

Relationship between the Therapeutic Dose of Arsenic Trioxide and Relapse in Acute Promyelocytic Leukemia

Huai Yu Wang
, Hui Yun Zhang
, Yuan Liu
, Xin Xin Zhang
, Sha Gong
, Li Mei Chen
, Meng Chang Wang
, Jie Ying Xi
, Xin Liu

Research output: Contribution to journal › Article › peer-review

1 Scopus citations

Abstract

OBJECTIVE: To analyze the correlation of ATO therapeutic dose with the relapse of patients with acute promyelocytic leukemia (APL) and to investigate the optimal dose and courses of ATO. METHODS: The clinical data of 102 patients with APL from January 2008 to June 2015 were analyzed retrospectively. The clinical characteristics of APL patients in relapsed group and maintained remission group were compared. According to ATO dose in 2 years recommended in chinese guideline as criteria of grouping, the patients were divided into ATO high and low dose groups, then the relapse rate in groups was compared. The cut-off value of ATO dose was analyzed by ROC curve. RESULTS: Univariate analysis showed that the relapse rate in high ATO and low ATO groups on 2 year treatment was 2.5% and 17.7% respectively (P<0.05); multiple variate analysis demonstrated that the ATO dose>22.4 mg/kg on 2 year treatment was independent preventive factor for the relapse of APL (OR=0.119, P<0.05). The ROC curve showed that the cut-off value of ATO dose on 2 year treatment was 8.765 mg/kg. The relapse rate of APL in group of ATO dose >8.765 mg/kg group was significantly lower than that in group of ATO dose <8.765 mg/kg. CONCLUSION: The relapse of APL relates with used ATO dose, sufficient use of ATO dose can decrease the relapse rate of APL.

Original language	English
Pages (from-to)	705-709
Number of pages	5
Journal	Zhongguo shi yan xue ye xue za zhi / Zhongguo bing li sheng li xue hui = Journal of experimental hematology / Chinese Association of Pathophysiology
Volume	26
Issue number	3
DOIs	https://doi.org/10.7534/j.issn.1009-2137.2018.03.012
State	Published - 1 Jun 2018
Externally published	Yes

Access to Document

10.7534/j.issn.1009-2137.2018.03.012

Cite this

Wang, H. Y., Zhang, H. Y., Liu, Y., Zhang, X. X., Gong, S., Chen, L. M., Wang, M. C., Xi, J. Y., & Liu, X. (2018). Relationship between the Therapeutic Dose of Arsenic Trioxide and Relapse in Acute Promyelocytic Leukemia. Zhongguo shi yan xue ye xue za zhi / Zhongguo bing li sheng li xue hui = Journal of experimental hematology / Chinese Association of Pathophysiology, 26(3), 705-709. https://doi.org/10.7534/j.issn.1009-2137.2018.03.012

@article{e46bb44914c2483db1a2bd96b27b389c,

title = "Relationship between the Therapeutic Dose of Arsenic Trioxide and Relapse in Acute Promyelocytic Leukemia",

abstract = "OBJECTIVE: To analyze the correlation of ATO therapeutic dose with the relapse of patients with acute promyelocytic leukemia (APL) and to investigate the optimal dose and courses of ATO. METHODS: The clinical data of 102 patients with APL from January 2008 to June 2015 were analyzed retrospectively. The clinical characteristics of APL patients in relapsed group and maintained remission group were compared. According to ATO dose in 2 years recommended in chinese guideline as criteria of grouping, the patients were divided into ATO high and low dose groups, then the relapse rate in groups was compared. The cut-off value of ATO dose was analyzed by ROC curve. RESULTS: Univariate analysis showed that the relapse rate in high ATO and low ATO groups on 2 year treatment was 2.5\% and 17.7\% respectively (P<0.05); multiple variate analysis demonstrated that the ATO dose>22.4 mg/kg on 2 year treatment was independent preventive factor for the relapse of APL (OR=0.119, P<0.05). The ROC curve showed that the cut-off value of ATO dose on 2 year treatment was 8.765 mg/kg. The relapse rate of APL in group of ATO dose >8.765 mg/kg group was significantly lower than that in group of ATO dose <8.765 mg/kg. CONCLUSION: The relapse of APL relates with used ATO dose, sufficient use of ATO dose can decrease the relapse rate of APL.",

author = "Wang, \{Huai Yu\} and Zhang, \{Hui Yun\} and Yuan Liu and Zhang, \{Xin Xin\} and Sha Gong and Chen, \{Li Mei\} and Wang, \{Meng Chang\} and Xi, \{Jie Ying\} and Xin Liu",

year = "2018",

month = jun,

day = "1",

doi = "10.7534/j.issn.1009-2137.2018.03.012",

language = "英语",

volume = "26",

pages = "705--709",

journal = "Zhongguo shi yan xue ye xue za zhi / Zhongguo bing li sheng li xue hui = Journal of experimental hematology / Chinese Association of Pathophysiology",

issn = "1009-2137",

publisher = "Haidian-qu",

number = "3",

}

Wang, HY, Zhang, HY, Liu, Y, Zhang, XX, Gong, S, Chen, LM, Wang, MC, Xi, JY & Liu, X 2018, 'Relationship between the Therapeutic Dose of Arsenic Trioxide and Relapse in Acute Promyelocytic Leukemia', Zhongguo shi yan xue ye xue za zhi / Zhongguo bing li sheng li xue hui = Journal of experimental hematology / Chinese Association of Pathophysiology, vol. 26, no. 3, pp. 705-709. https://doi.org/10.7534/j.issn.1009-2137.2018.03.012

Relationship between the Therapeutic Dose of Arsenic Trioxide and Relapse in Acute Promyelocytic Leukemia. / Wang, Huai Yu; Zhang, Hui Yun; Liu, Yuan et al.
In: Zhongguo shi yan xue ye xue za zhi / Zhongguo bing li sheng li xue hui = Journal of experimental hematology / Chinese Association of Pathophysiology, Vol. 26, No. 3, 01.06.2018, p. 705-709.

Research output: Contribution to journal › Article › peer-review

TY - JOUR

T1 - Relationship between the Therapeutic Dose of Arsenic Trioxide and Relapse in Acute Promyelocytic Leukemia

AU - Wang, Huai Yu

AU - Zhang, Hui Yun

AU - Liu, Yuan

AU - Zhang, Xin Xin

AU - Gong, Sha

AU - Chen, Li Mei

AU - Wang, Meng Chang

AU - Xi, Jie Ying

AU - Liu, Xin

PY - 2018/6/1

Y1 - 2018/6/1

N2 - OBJECTIVE: To analyze the correlation of ATO therapeutic dose with the relapse of patients with acute promyelocytic leukemia (APL) and to investigate the optimal dose and courses of ATO. METHODS: The clinical data of 102 patients with APL from January 2008 to June 2015 were analyzed retrospectively. The clinical characteristics of APL patients in relapsed group and maintained remission group were compared. According to ATO dose in 2 years recommended in chinese guideline as criteria of grouping, the patients were divided into ATO high and low dose groups, then the relapse rate in groups was compared. The cut-off value of ATO dose was analyzed by ROC curve. RESULTS: Univariate analysis showed that the relapse rate in high ATO and low ATO groups on 2 year treatment was 2.5% and 17.7% respectively (P<0.05); multiple variate analysis demonstrated that the ATO dose>22.4 mg/kg on 2 year treatment was independent preventive factor for the relapse of APL (OR=0.119, P<0.05). The ROC curve showed that the cut-off value of ATO dose on 2 year treatment was 8.765 mg/kg. The relapse rate of APL in group of ATO dose >8.765 mg/kg group was significantly lower than that in group of ATO dose <8.765 mg/kg. CONCLUSION: The relapse of APL relates with used ATO dose, sufficient use of ATO dose can decrease the relapse rate of APL.

AB - OBJECTIVE: To analyze the correlation of ATO therapeutic dose with the relapse of patients with acute promyelocytic leukemia (APL) and to investigate the optimal dose and courses of ATO. METHODS: The clinical data of 102 patients with APL from January 2008 to June 2015 were analyzed retrospectively. The clinical characteristics of APL patients in relapsed group and maintained remission group were compared. According to ATO dose in 2 years recommended in chinese guideline as criteria of grouping, the patients were divided into ATO high and low dose groups, then the relapse rate in groups was compared. The cut-off value of ATO dose was analyzed by ROC curve. RESULTS: Univariate analysis showed that the relapse rate in high ATO and low ATO groups on 2 year treatment was 2.5% and 17.7% respectively (P<0.05); multiple variate analysis demonstrated that the ATO dose>22.4 mg/kg on 2 year treatment was independent preventive factor for the relapse of APL (OR=0.119, P<0.05). The ROC curve showed that the cut-off value of ATO dose on 2 year treatment was 8.765 mg/kg. The relapse rate of APL in group of ATO dose >8.765 mg/kg group was significantly lower than that in group of ATO dose <8.765 mg/kg. CONCLUSION: The relapse of APL relates with used ATO dose, sufficient use of ATO dose can decrease the relapse rate of APL.

UR - https://www.scopus.com/pages/publications/85056622936

U2 - 10.7534/j.issn.1009-2137.2018.03.012

DO - 10.7534/j.issn.1009-2137.2018.03.012

M3 - 文章

C2 - 29950207

AN - SCOPUS:85056622936

SN - 1009-2137

VL - 26

SP - 705

EP - 709

JO - Zhongguo shi yan xue ye xue za zhi / Zhongguo bing li sheng li xue hui = Journal of experimental hematology / Chinese Association of Pathophysiology

JF - Zhongguo shi yan xue ye xue za zhi / Zhongguo bing li sheng li xue hui = Journal of experimental hematology / Chinese Association of Pathophysiology

IS - 3

ER -

Wang HY, Zhang HY, Liu Y, Zhang XX, Gong S, Chen LM et al. Relationship between the Therapeutic Dose of Arsenic Trioxide and Relapse in Acute Promyelocytic Leukemia. Zhongguo shi yan xue ye xue za zhi / Zhongguo bing li sheng li xue hui = Journal of experimental hematology / Chinese Association of Pathophysiology. 2018 Jun 1;26(3):705-709. doi: 10.7534/j.issn.1009-2137.2018.03.012

Relationship between the Therapeutic Dose of Arsenic Trioxide and Relapse in Acute Promyelocytic Leukemia

Abstract

Access to Document

Other files and links

Fingerprint

Cite this